StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Kovai Medical Center & Hospital Limited (KOVAI)

Hospitals & Diagnostics · NSE · end-of-day 2026-10-19
Close
₹5,875.00
Day change
-1.64%
1-year
+197.3%
From 52-week high
-6.6%
Weinstein stage
Stage 2
Minervini template
7/8
Kovai Medical Center & Hospital Limited closed at ₹5,875.00 on 2026-10-19, up 197% over the past year, 7% below its 52-week high. It meets 7 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 2 - advancing. Over the year its annualised volatility was about 116%, with a largest fall of 14% from a peak.

About Kovai Medical Center & Hospital Limited

Kovai Medical Center and Hospital Limited operates hospitals and healthcare facilities providing medical, surgical and diagnostic services. Its business benefits from increasing healthcare spending, rising medical awareness and demand for specialized treatment. Expansion of hospital capacity, higher occupancy and specialty services can support growth. Occupancy, case volumes, pricing, doctor availability, operating costs, capital expenditure and competition remain important factors.

Price, RSI and MACD

Price · +7.1% over the period
2,1433,2394,3355,4316,527Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
RSI (14) · 39.1
305070
MACD (12, 26, 9) · histogram -6.32
-218.470358.4646.8935.2
Price · +196.9% over the period
1,4522,7304,0095,2876,566Apr 23Jun 23Aug 23Oct 23May 26Jul 26Sep 26
RSI (14) · 39.1
305070
MACD (12, 26, 9) · histogram -6.32
-218.470358.4646.8935.2
Price · +239.6% over the period
1,0492,4343,8195,2046,589Apr 22Aug 22Dec 22Apr 23Aug 23May 26Sep 26
RSI (14) · 39.1
305070
MACD (12, 26, 9) · histogram -6.32
-216.271.1358.3645.6932.8
Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market capSales (TTM)Net profit (TTM)P/EEPS (TTM)P/BROEBeta
₹6,429 cr——25.5234.254.8719.4%—

Investor methods

MethodChecksScoreVerdict
Minervini
✓ Close above the 150- and 200-day averages
✓ 150-day above 200-day
✓ 200-day rising for a month
✓ 50-day above the 150- and 200-day
✗ Close above the 50-day
✓ At least 25% above the 52-week low · low 1,953.90
✓ Within 25% of the 52-week high · high 6,292.00
✓ RS percentile 70 or more · RS 97
Trend template - the gate, measured: a modest 21-day edge.
7/87 of 8
Weinstein
Stan Weinstein's stage analysis on the 30-week moving average.
Stage 2 - advancing
CAN SLIM
— C latest quarter EPS up 25%+
— A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held
✓ N within 15% of the 52-week high · high 6,292.00
✗ S more volume on up days than down days (50 sessions) · 0.87x
✓ L RS percentile 80 or more · RS 97
— I institutional sponsorship rising · shareholding not collected yet
✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45%
William O'Neil's growth-leader checklist.
3/4Average
Darvas
✓ Box top confirmed (3 sessions below the new high) · top 6,444.00
✓ Box bottom confirmed (3 sessions holding) · bottom 5,848.00
✗ Close above the box top · close 5,875.00
✗ Volume at least 1.5x its 50-day average · 0.8x
Nicolas Darvas's box: buy the breakout above a confirmed box after a new high.
57/100In box
Turtle
✗ Close above the prior 55-session high · 6,444.00
✗ Close above the prior 20-session high · 6,334.50
✗ Close below the prior 20-session low · 5,848.00
Donchian channel breakout - the Turtle traders' entry.
No signal
Graham
✗ Price at or below the Graham number · Graham number 2,521.57
✗ P/E 15 or less · P/E 25.1
✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 4.87
— Current ratio 2 or more
— 10 years of positive earnings, 20 of dividends · history not held
Benjamin Graham's defensive-investor tests.
43/100Expensive
Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Hospitals & Diagnostics sector — top 10 by 1-year return

Stock1M %3M %6M %1Y %3Y %5Y %P/EP/BROE %ROCE %ROA %D/EEV/EBITDA₹ CrSales TTM ₹ CrProfit TTM ₹ CrEPSBeta
KOVAI this stock-5.6-0.9+7.0+128.0+118.8+256.025.54.8719.4————6,429——234.2—
SAKAR-21.8+2.7+51.5+162.7+158.4+464.357.06.3310.012.9—0.1730.82,0542723616.20.69
AHCL+17.8+79.8+86.2+112.4——11.16.2347.4——0.1930.71,434——2.40.44
VIJAYA-12.2+2.5+33.7+37.9+134.0+143.875.114.7119.730.3—0.0039.614,07885718818.20.54
ENTERO-13.2+26.4+18.2+35.9——52.23.886.710.7—0.3426.46,5457,12816828.80.36
AMANTA-13.3-0.0+21.9+34.8——39.62.57———1.06——291154.20.73
YATHARTH-14.8+14.4+30.6+19.8+147.7—51.65.1810.012.4—0.1430.29,3561,33417418.80.88
LALPATHLAB-2.8+8.9+30.0+18.6+47.0-0.356.812.3221.629.1—0.0036.230,9002,89154632.50.41
THYROCARE-15.3-15.2+19.9+13.6+151.4+22.742.612.8028.837.8—0.0028.27,49787617611.10.47
STARHEALTH-0.9-6.7+7.0+7.6-8.9—35.73.158.9————31,904——15.30.41
METROPOLIS-13.1-9.5+9.2+7.1+37.5-24.553.47.1113.419.6—0.0126.310,7631,7102039.70.43
A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Hospitals & Diagnostics stocks of a similar size

Entero Healthcare Solutions LimitedNephroplusMedplus HealthThyrocare TechnologiesSanofi Consumer Healthcare India LimitedHcgZota Health Care LimitedYatharth
The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →
Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.
For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.